August 23, 2024Open Access

Effectiveness of rVSV-ZEBOV vaccination during the 2018–20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study

Key Points

Key points are not available for this paper at this time.

Abstract

The recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) vaccine is the only WHO prequalified vaccine recommended for use to respond to outbreaks of Ebola virus (species Zaire ebolavirus) by WHO's Strategic Advisory Group of Experts on Immunization. Despite the vaccine's widespread use during several outbreaks, no real-world effectiveness estimates are currently available in the literature.

Read Full Paperexternally

KI fragen

Bookmark

View Full Paper

Cite This Study

Meakin et al. (Fri,) studied this question.

synapsesocial.com/papers/68e5b146b6db64358754aedc https://doi.org/https://doi.org/10.1016/s1473-3099(24)00419-5

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

KI fragen

Bookmark

View Full Paper